α2β1 Integrin specific inhibitor BTT-3033 promotes paclitaxel-induced apoptosis in human ovarian cancer cells

Zeinab Babaei , Mahdi Amani, Mohsen Minaiyan, Seyedeh Sara Ghorbanhosseini, Mahmoud Aghaei

Abstract


Background and purpose: The new plan of using molecular targeted agents in combination with cytotoxic drugs may represent a promising strategy to increase the efficacy of chemotherapy. Hence, we examined whether α2β1 integrin-specific inhibitor, BTT-3033, could modulate the susceptibility of OVCAR3 and SKOV3 ovarian cancer cells to paclitaxel (PTX).

Experimental approach: Ovarian cancer cell lines were treated with BTT-3033 and different concentrations of PTX. To determine the mechanisms involved in the PTX/BTT-3033 combination-induced cell death, cell viability, apoptosis, reactive oxygen species (ROS) production, mitochondrial membrane potential (MMP), and caspase-3 activity were evaluated.

Findings/Results: Both BTT-3033 (≥ 1 µM) and PTX (≥ 0.01 µM) suppressed the proliferation of OVCAR3 and SKOV3 cells in a concentration-related manner. Pretreatment with BTT-3033 (1 µM), followed by                PTX-induced synergistic antiproliferative effects, decreased the IC50 values of PTX from 0.45 to 0.03 µM in OVCAR3 and 0.35 to 0.02 µM in SKOV3 cells. All of the coefficients of drug interaction for various PTX and BTT-3033 combinations were found to be less than 1. Moreover, PTX/BTT-3033 combination induced more apoptotic cells (from 4.2% to 87.0% in OVCAR3 and 2.4% to 88.5% in SKOV3) than PTX alone. Combination therapy also decreased MMP and increased the caspase-3 activity. Additionally, we found that the PTX/BTT-3033 combination enhanced ROS production in OVCAR3 and SKOV3 cells.

Conclusion and implications: BTT-3033 has demonstrated the ability to enhance the susceptibility of ovarian cancer cells to PTX by inducing MMP loss, ROS production, and mitochondrial apoptosis, therefore this combination therapy might represent a promising strategy for ovarian cancer treatment.

 

 


Keywords


Apoptosis; BTT-3033; Drug interaction; Ovarian cancer; Paclitaxel.

Full Text:

PDF

References


Naci D, Vuori K, Aoudjit F. Alpha2beta1 integrin in cancer development and chemoresistance. Semin Cancer Biol. 2015;35:145-153.DOI: 10.1016/j.semcancer.2015.08.004.

Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract. 2012;2012:283181,1-16.DOI: 10.1155/2012/283181.

Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001;20(36):4995-5004.DOI: 10.1038/sj.onc.1204554.

Cohen E, Tendler T, Lu H, Hansen CK, Kertsman J, Barrios J, et al. Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling. Anticancer Res 2013;33(2):379-386.PMID: 23393327.

Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 2004;10(21): 7427-7437.DOI: 10.1158/1078-0432.CCR-03-0825.

Li X, Ishihara S, Yasuda M, Nishioka T, Mizutani T, Ishikawa M, et al. Lung cancer cells that survive ionizing radiation show increased integrin α2β1- and EGFR-dependent invasiveness. PLoS One. 2013;8(8):e70905,1-12.DOI: 10.1371/journal.pone.0070905.

Hodkinson PS, Elliott T, Wong WS, Rintoul RC, Mackinnon AC, Haslett C, et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 2006;13(10):1776-1788.DOI: 10.1038/sj.cdd.4401849.

Zheng W, Ge D, Meng G. Reversing microtubule-directed chemotherapeutic drug resistance by co-delivering α2β1 inhibitor and paclitaxel with nanoparticles in ovarian cancer. Cell Biol Int. 2020;44(2):610-620.DOI: 10.1002/cbin.11261.

Morazzani M, de Carvalho DD, Kovacic H, Smida-Rezgui S, Briand C, Penel C. Monolayer versus aggregate balance in survival process for EGF-induced apoptosis in A431 carcinoma cells: implication of ROS-P38 MAPK-integrin alpha2beta1 pathway. Int J Cancer. 2004;110:788-799.DOI: 10.1002/ijc.20198.

Mikuła-Pietrasik J, Witucka A, Pakuła M, Uruski P, Begier-Krasińska B, Niklas A, et al. A comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects the biology of normal cells. Cell Mol Life Sci. 2019;76(4):681-697.DOI: 10.1007/s00018-018-2954-1.

Kigawa J. New strategy for overcoming resistance to chemotherapy of ovarian cancer. Yonago Acta Med. 2013;56(2):43-50.PMID: 24031151.

Nissinen L, Koivunen J, Käpylä J, Salmela M, Nieminen J, Jokinen J, et al. Novel α2β1 integrin inhibitors reveal that integrin binding to collagen under shear stress conditions does not require receptor preactivation. J Biol Chem. 2012;287(53):44694-44702.DOI: 10.1074/jbc.M111.309450.

Salemi Z, Azizi R, Fallahian F, Aghaei M. Integrin α2β1 inhibition attenuates prostate cancer cell proliferation by cell cycle arrest, promoting apoptosis and reducing epithelial-mesenchymal transition. J Cell Physiol. 2021;236(7): 4954-4965.DOI: 10.1002/jcp.30202.

Babaei Z, Panjehpour M, Parsian H, Aghaei M. SAR131675 receptor tyrosine kinase inhibitor induces apoptosis through Bcl-2/Bax/Cyto c mitochondrial pathway in human umbilical vein endothelial cells. Anticancer Agents Med Chem. 2022;22(5):943-950.DOI: 10.2174/1871520621666210708102619.

Chen L, Ye HL, Zhang G, Yao WM, Chen XZ, Zhang FC, et al. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells. PLoS One. 2014;9(1):e85771,1-12.DOI: 10.1371/journal.pone.0085771.

Ye Y, Zhang T, Yuan H, Li D, Lou H, Fan P. Mitochondria-targeted lupane triterpenoid derivatives and their selective apoptosis-inducing anticancer mechanisms. J Med Chem. 2017;60(14):6353-6363.DOI: 10.1021/acs.jmedchem.7b00679.

Villegas-Pineda JC, Garibay-Cerdenares OL, Hernández-Ramírez VI, Gallardo-Rincón D, Cantú de León D, Pérez-Montiel-Gómez MD, et al. Integrins and haptoglobin: molecules overexpressed in ovarian cancer. Pathol Res Pract. 2015;211(12):973-981.DOI: 10.1016/j.prp.2015.10.002.

Hu Z, Gao S, Gao J, Hou R, Liu C, Liu J, et al. Elevated levels of Lewis y and integrin α5β1 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma. Int J Mol Sci. 2012;13(12):15588-15600.DOI: 10.3390/ijms131215588.

Scalici JM, Harrer C, Allen A, Jazaeri A, Atkins KA, McLachlan KR, et al. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin. Gynecol Oncol. 2014;132(2):455-461.DOI: 10.1016/j.ygyno.2013.12.031.

Zhang L, Zou W. Inhibition of integrin β1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway. Mol Med Rep. 2015;12(6): 7869-7876.DOI: 10.3892/mmr.2015.4443.

Dötzer K, Schlüter F, Koch FEV, Brambs CE, Anthuber S, Frangini S, et al. Integrin α2β1 represents a prognostic and predictive biomarker in primary ovarian cancer. Biomedicines. 2021;9(3):289.DOI: 10.3390/biomedicines9030289.

Czogalla B, Dötzer K, Sigrüner N, von Koch FE, Brambs CE, Anthuber S, et al. Combined expression of HGFR with Her2/neu, EGFR, IGF1R, mucin-1 and integrin α2β1 is associated with aggressive epithelial ovarian cancer. Biomedicines. 2022;10(11):2694.DOI: 10.3390/biomedicines10112694.

Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019;35(3):347-367.DOI: 10.1016/j.ccell.2019.01.007.

Jakubzig B, Baltes F, Henze S, Schlesinger M, Bendas G. Mechanisms of matrix-induced chemoresistance of breast cancer cells-deciphering novel potential targets for a cell sensitization. Cancers. 2018;10(12):495,1-20.DOI: 10.3390/cancers10120495.

Yuan J, Liu M, Yang L, Tu G, Zhu Q, Chen M, et al. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells. Breast Cancer Res. 2015;17(1):69,1-18.DOI: 10.1186/s13058-015-0579-y.

Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D'Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016;8(4):603-619.DOI: 10.18632/aging.100934.

Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022;12:985363,1-16.DOI: 10.3389/fonc.2022.985363.

Shahali A, Ghanadian M, Jafari SM, Aghaei M. Mitochondrial and caspase pathways are involved in the induction of apoptosis by nardosinen in MCF-7 breast cancer cell line. Res Pharm Sci. 2018;13(1): 12-21.DOI: 10.4103/1735-5362.220963.

Jafari SM, Nazri A, Shabani M, Balajam NZ, Aghaei M. Galectin-9 induces apoptosis in OVCAR-3 ovarian cancer cell through mitochondrial pathway. Res Pharm Sci. 2018;13(6):557-565.DOI: 10.4103/1735-5362.245967.

Zargar Balajam N, Shabani M, Aghaei M. Galectin-9 inhibits cell proliferation and induces apoptosis in Jurkat and KE-37 acute lymphoblastic leukemia cell lines via caspase-3 activation. Res Pharm Sci. 2021;16(6):612-622.DOI: 10.4103/1735-5362.327507.

Kutuk O, Letai A. Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ. 2010;17(10):1624-1635.DOI: 10.1038/cdd.2010.41.

Sherman-Baust CA, Becker KG, Wood Iii WH, Zhang Y, Morin PJ. Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J Ovarian Res. 2011;4(1):21,1-11.DOI: 10.1186/1757-2215-4-21.

Alexandre J, Hu Y, Lu W, Pelicano H, Huang P. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res. 2007; 67(8):3512-3517.DOI: 10.1158/0008-5472.CAN-06-3914.

Naci D, El Azreq MA, Chetoui N, Lauden L, Sigaux F, Charron D, et al. α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J Biol Chem. 2012;287(21):17065-17076.DOI: 10.1074/jbc.M112.349365.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.